Quest Diagnostics Incorporated (DGX) - Net Assets
Based on the latest financial reports, Quest Diagnostics Incorporated (DGX) has net assets worth $7.67 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.67 Billion) and total liabilities ($9.01 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Quest Diagnostics Incorporated to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.67 Billion |
| % of Total Assets | 45.98% |
| Annual Growth Rate | 9.4% |
| 5-Year Change | 11.03% |
| 10-Year Change | 53.81% |
| Growth Volatility | 13.54 |
Quest Diagnostics Incorporated - Net Assets Trend (1996–2025)
This chart illustrates how Quest Diagnostics Incorporated's net assets have evolved over time, based on quarterly financial data. See how many days can Quest Diagnostics Incorporated fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Quest Diagnostics Incorporated (1996–2025)
The table below shows the annual net assets of Quest Diagnostics Incorporated from 1996 to 2025. For live valuation and market cap data, see DGX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.29 Billion | +5.66% |
| 2024-12-31 | $6.90 Billion | +7.45% |
| 2023-12-31 | $6.42 Billion | +6.84% |
| 2022-12-31 | $6.01 Billion | -8.46% |
| 2021-12-31 | $6.56 Billion | -4.77% |
| 2020-12-31 | $6.89 Billion | +19.57% |
| 2019-12-31 | $5.76 Billion | +7.84% |
| 2018-12-31 | $5.34 Billion | +6.14% |
| 2017-12-31 | $5.04 Billion | +6.29% |
| 2016-12-31 | $4.74 Billion | -0.96% |
| 2015-12-31 | $4.78 Billion | +10.46% |
| 2014-12-31 | $4.33 Billion | +8.99% |
| 2013-12-31 | $3.97 Billion | -5.08% |
| 2012-12-31 | $4.19 Billion | +12.67% |
| 2011-12-31 | $3.71 Billion | -8.36% |
| 2010-12-31 | $4.05 Billion | +1.06% |
| 2009-12-31 | $4.01 Billion | +11.28% |
| 2008-12-31 | $3.60 Billion | +8.44% |
| 2007-12-31 | $3.32 Billion | +10.10% |
| 2006-12-31 | $3.02 Billion | +9.27% |
| 2005-12-31 | $2.76 Billion | +20.73% |
| 2004-12-31 | $2.29 Billion | -4.43% |
| 2003-12-31 | $2.39 Billion | +35.38% |
| 2002-12-31 | $1.77 Billion | +32.40% |
| 2001-12-31 | $1.34 Billion | +29.48% |
| 2000-12-31 | $1.03 Billion | +19.55% |
| 1999-12-31 | $863.10 Million | +51.98% |
| 1998-12-31 | $567.90 Million | +4.84% |
| 1997-12-31 | $541.70 Million | +0.55% |
| 1996-12-31 | $538.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quest Diagnostics Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1062189200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $9.99 Billion | 139.39% |
| Common Stock | $2.00 Million | 0.03% |
| Other Comprehensive Income | $-27.00 Million | -0.38% |
| Total Equity | $7.17 Billion | 100.00% |
Quest Diagnostics Incorporated Competitors by Market Cap
The table below lists competitors of Quest Diagnostics Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CIMB Group Holdings Bhd
KLSE:1023
|
$20.75 Billion |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
$20.78 Billion |
|
Expand Energy Corporation
NASDAQ:EXE
|
$20.81 Billion |
|
Veralto Corporation
NYSE:VLTO
|
$20.86 Billion |
|
Cognizant Technology Solutions Corp Class A
NASDAQ:CTSH
|
$20.67 Billion |
|
Hapag Lloyd AG
XETRA:HLAG
|
$20.67 Billion |
|
CyberArk Software Ltd
NASDAQ:CYBR
|
$20.64 Billion |
|
King Slide Works Co Ltd
TW:2059
|
$20.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quest Diagnostics Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,778,000,000 to 7,170,000,000, a change of 392,000,000 (5.8%).
- Net income of 992,000,000 contributed positively to equity growth.
- Dividend payments of 353,000,000 reduced retained earnings.
- Share repurchases of 450,000,000 reduced equity.
- Other comprehensive income increased equity by 61,000,000.
- Other factors increased equity by 142,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $992.00 Million | +13.84% |
| Dividends Paid | $353.00 Million | -4.92% |
| Share Repurchases | $450.00 Million | -6.28% |
| Other Comprehensive Income | $61.00 Million | +0.85% |
| Other Changes | $142.00 Million | +1.98% |
| Total Change | $- | 5.78% |
Book Value vs Market Value Analysis
This analysis compares Quest Diagnostics Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.51x to 3.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $4.59 | $195.00 | x |
| 1997-12-31 | $4.66 | $195.00 | x |
| 1998-12-31 | $4.70 | $195.00 | x |
| 1999-12-31 | $6.35 | $195.00 | x |
| 2000-12-31 | $5.46 | $195.00 | x |
| 2001-12-31 | $6.83 | $195.00 | x |
| 2002-12-31 | $8.87 | $195.00 | x |
| 2003-12-31 | $11.08 | $195.00 | x |
| 2004-12-31 | $10.77 | $195.00 | x |
| 2005-12-31 | $13.44 | $195.00 | x |
| 2006-12-31 | $15.13 | $195.00 | x |
| 2007-12-31 | $17.02 | $195.00 | x |
| 2008-12-31 | $18.39 | $195.00 | x |
| 2009-12-31 | $21.24 | $195.00 | x |
| 2010-12-31 | $22.75 | $195.00 | x |
| 2011-12-31 | $23.19 | $195.00 | x |
| 2012-12-31 | $26.00 | $195.00 | x |
| 2013-12-31 | $25.80 | $195.00 | x |
| 2014-12-31 | $29.66 | $195.00 | x |
| 2015-12-31 | $32.30 | $195.00 | x |
| 2016-12-31 | $32.59 | $195.00 | x |
| 2017-12-31 | $35.15 | $195.00 | x |
| 2018-12-31 | $37.53 | $195.00 | x |
| 2019-12-31 | $41.48 | $195.00 | x |
| 2020-12-31 | $49.70 | $195.00 | x |
| 2021-12-31 | $50.34 | $195.00 | x |
| 2022-12-31 | $49.94 | $195.00 | x |
| 2023-12-31 | $55.81 | $195.00 | x |
| 2024-12-31 | $59.98 | $195.00 | x |
| 2025-12-31 | $63.45 | $195.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quest Diagnostics Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.84%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.99%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 2.26x
- Recent ROE (13.84%) is above the historical average (10.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -116.19% | -38.73% | 1.16x | 2.59x | $-679.83 Million |
| 1997 | -4.12% | -1.46% | 1.09x | 2.59x | $-76.47 Million |
| 1998 | 4.74% | 1.84% | 1.07x | 2.40x | $-29.89 Million |
| 1999 | -0.39% | -0.15% | 0.77x | 3.34x | $-89.71 Million |
| 2000 | 9.89% | 2.98% | 1.19x | 2.78x | $-1.13 Million |
| 2001 | 12.15% | 4.47% | 1.24x | 2.19x | $28.70 Million |
| 2002 | 18.21% | 7.84% | 1.24x | 1.88x | $145.27 Million |
| 2003 | 18.24% | 9.22% | 1.10x | 1.80x | $197.25 Million |
| 2004 | 21.81% | 9.74% | 1.22x | 1.84x | $270.33 Million |
| 2005 | 19.77% | 9.93% | 1.04x | 1.92x | $269.98 Million |
| 2006 | 19.42% | 9.35% | 1.11x | 1.88x | $284.50 Million |
| 2007 | 10.23% | 5.07% | 0.78x | 2.58x | $7.51 Million |
| 2008 | 16.13% | 8.02% | 0.86x | 2.33x | $221.01 Million |
| 2009 | 18.28% | 9.78% | 0.87x | 2.15x | $330.14 Million |
| 2010 | 17.87% | 9.78% | 0.86x | 2.11x | $317.56 Million |
| 2011 | 12.67% | 6.27% | 0.81x | 2.51x | $99.10 Million |
| 2012 | 13.35% | 7.53% | 0.80x | 2.23x | $139.39 Million |
| 2013 | 21.50% | 11.88% | 0.80x | 2.27x | $454.20 Million |
| 2014 | 12.93% | 7.48% | 0.75x | 2.30x | $125.90 Million |
| 2015 | 15.14% | 9.46% | 0.75x | 2.13x | $240.60 Million |
| 2016 | 13.94% | 8.58% | 0.74x | 2.18x | $182.20 Million |
| 2017 | 15.69% | 10.01% | 0.73x | 2.13x | $279.90 Million |
| 2018 | 14.11% | 9.77% | 0.68x | 2.11x | $214.40 Million |
| 2019 | 15.21% | 11.11% | 0.60x | 2.28x | $293.90 Million |
| 2020 | 21.17% | 15.16% | 0.67x | 2.08x | $755.10 Million |
| 2021 | 30.96% | 18.49% | 0.79x | 2.11x | $1.35 Billion |
| 2022 | 16.05% | 9.57% | 0.77x | 2.18x | $356.70 Million |
| 2023 | 13.54% | 9.23% | 0.66x | 2.22x | $223.30 Million |
| 2024 | 12.85% | 8.82% | 0.61x | 2.38x | $193.20 Million |
| 2025 | 13.84% | 8.99% | 0.68x | 2.26x | $275.00 Million |
Industry Comparison
This section compares Quest Diagnostics Incorporated's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $836,732,192
- Average return on equity (ROE) among peers: -59.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $7.67 Billion | -116.19% | 1.17x | $20.74 Billion |
| Agilent Technologies Inc (A) | $5.84 Billion | 21.21% | 0.84x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.66 Million | -167.28% | 1.68x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $-1.47 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $41.17 Million | -76.16% | 1.94x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $63.90 Million |
| CareDx Inc (CDNA) | $-5.95 Million | 0.00% | 0.00x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagn… Read more